Scleroderma (Systemic Sclerosis) Treatment Market Size 2020-2026 | Leading Players are A.C. PHARMA, Pfizer Inc., Eli Lilly and Company, Bayer AG

(CDN Newswire via Comtex)

The global scleroderma (systemic sclerosis) treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of scleroderma (systemic sclerosis) treatment market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Get Sample PDF Copy of this Report @

Segmentation: Global Scleroderma (Systemic Sclerosis) Treatment Market

By Type

  • Limited
  • Diffuse

By Therapeutics

  • Immunosuppressant
  • Calcium-Channel Blockers
  • Endothelin Receptor Antagonists
  • PDE-5 Inhibitors
  • Prostacyclin Analogues
  • ACE Inhibitors

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

Key Developments in the Market:

  • In September, 2016 European Medicines Agency and US Food and Drug Administration granted Boehringer Ingelheim International GmbH's Ofev drug Orphan Drug Designation for the treatment of systemic sclerosis
  • In July, 2018 Combined Response Index for Systemic Sclerosis was presented at the European Congress of Rheumatology, which was presented to determine the effects of drugs in patients with systemic sclerosis.

Reasons to Purchase this Report:

  • Current and future of global scleroderma (systemic sclerosis) treatment market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Buy Full Report Now @

Global Scleroderma (Systemic Sclerosis) Treatment Market report explains better market perspective in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. Market segmentation is a significant parameter that categorises the market depending upon application, vertical, deployment model, end-user, and geography etc. Additionally, this report has been structured by keeping in mind all the foremost aspects of the market research that put forth market landscape simply into focus. All inclusive Global Scleroderma (Systemic Sclerosis) Treatment Market report involves use of latest tools and techniques for researching, analysing and gathering of data and information.

Global Scleroderma (Systemic Sclerosis) Treatment Market, By Type (Limited, Diffuse), By Therapeutics (Immunosuppressant, Calcium-Channel Blockers, Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin Analogues, ACE Inhibitors), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026 With increased healthcare infrastructure, the need for disease-modifying therapies for systemic sclerosis has increased. This has induced the global scleroderma (systemic sclerosis) treatment market to grow considerably during the forecast period of 2019 to 2026. The upcoming market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Key Market Competitors: Global Scleroderma (Systemic Sclerosis) Treatment Market

Actelion Pharmaceuticals Ltd,

Hoffmann-La Roche Ltd,

Bristol-Myers Squibb Company,

Boehringer Ingelheim International GmbH,


GlaxoSmithKline plc.,


Novartis AG,

Teva Pharmaceutical Industries Ltd.,




Asta Pharma,

Aspen Holdings,


Pfizer Inc.,

Eli Lilly and Company,

Bayer AG,

Argentis Pharmaceuticals LLC.,



Amgen Inc.,

Corbus Pharmaceuticals Holdings Inc.,


Cumberland Pharmaceuticals

Market Definition: Global Scleroderma (Systemic Sclerosis) Treatment Market

Systemic sclerosis is a chronic autoimmune disorder characterized by the skin hardening, inflammation in multiple organs; the most common characteristic is thickening of skin in this disease. The exact cause of the disease is unknown but it is known to have an overproduction of collagen in the body. The disease is associated with high rates of mortality and lack of any therapeutics for the disease is affecting the market growth. Due to the disease's effects on multiple organs, the treatments available are for the different affected areas and not the disease itself.

Market Drivers:

  • Increased investment in research & development for the development of treatment for systemic sclerosis is expected to drive the market growth
  • Rise in number of government initiatives and programs for the awareness of the disease and treatment options available is also expected to drive the market growth

Market Restraints:

  • Lack of a particular treatment for the disease and only options available for the symptoms of the disease is expected to act as a restraint to the market growth
  • Diagnosis and cause of the disease are still unknown which makes the selection of drugs for symptoms reliefs even more difficult for doctors as every case of scleroderma is different, this trend is expected to act as a restraint for the market growth

To Know More About This Report @

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at [email protected].